Results 1 to 10 of about 3,785 (146)

Prophylaxis With Valganciclovir in Anti-Melanoma Differentiation Associated 5 Gene Antibody Dermatomyositis: A Cohort Study in China.

Journal of clinical rheumatology
BACKGROUND Cytomegalovirus (CMV) infection is prevalent in patients with anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis (MDA5+DM) and affects the prognosis.
Shanshan Li, Xiaoxing Wang, Zhang Ling, J. Duan, Liu Xia, Zhang Lu   +5 more
semanticscholar   +1 more source

Pharmacokinetics, Pharmacodynamics, and Therapeutic Drug Monitoring of Valganciclovir and Ganciclovir in Transplantation

Clinical pharmacology and therapy, 2021
Ganciclovir and valganciclovir are first choice drugs for the prevention and treatment of cytomegalovirus infection and disease in solid organ and stem cell transplant recipients.
Bénédicte Franck, J. Autmizguine, P. Marquet, P. Ovetchkine, J. Woillard   +4 more
semanticscholar   +1 more source

Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients

Transplant Infectious Disease
Lung transplant recipients are at high risk for severe cytomegalovirus (CMV) disease. Off‐label use of letermovir (LET) may avert myelotoxicity associated with valganciclovir (VGCV), but data in lung transplantation are limited.
Sydni Martinez, D. Sindu, M. Nailor, L. Cherrier, S. Tokman, Rajat Walia, K. Goodlet   +6 more
semanticscholar   +1 more source

EFFICACY OF MARIBAVIR IN VALGANCICLOVIR-RESISTANT CYTOMEGALOVIRUS RETINITIS

Retinal cases & brief reports, 2022
Treatment of cytomegalovirus retinitis is complicated by resistance to current standard therapy, such as valganciclovir. Maribavir is a new therapy that recently completed Phase 3 trial for resistant or refractory cytomegalovirus infection.
Jonathan C. Tsui, Vincent Huang, A. Kolomeyer, Charles G. Miller, A.D. Mishkin, A. Maguire   +5 more
semanticscholar   +1 more source

In utero treatment of congenital cytomegalovirus infection with valganciclovir: an observational study on safety and effectiveness.

Journal of Antimicrobial Chemotherapy
BACKGROUND The treatment of congenital cytomegalovirus (CMV) infection is usually administered to neonates after birth; however, it can be anticipated during the prenatal period by treating pregnant women in order to reduce the severity of the congenital
N. Bourgon, R. López, J. Fourgeaud, T. Guilleminot, L. Bussières, J. Magny, Y. Ville, Marianne Leruez Ville   +7 more
semanticscholar   +1 more source

Application of machine-learning models to predict the ganciclovir and valganciclovir exposure in children using a limited sampling strategy

Antimicrobial Agents and Chemotherapy
Intravenous ganciclovir and oral valganciclovir display significant variability in ganciclovir pharmacokinetics, particularly in children. Therapeutic drug monitoring currently relies on the area under the concentration-time (AUC).
Laure Ponthier, Bénédicte Franck, Julie Autmizguine, M. Labriffe, Philippe Ovetchkine, P. Marquet, Anders Åsberg, J. Woillard   +7 more
semanticscholar   +1 more source

Novel risk factor for valganciclovir toxicity—NUDT15 genetic variant

Transplant Infectious Disease, 2022
Recent “in vitro” studies describe nucleoside diphosphate–linked moiety X-type motif 15 (NUDT15) enzyme to be involved in the metabolismofganciclovir. 1,2 Wereportsevereleukopeniaduringther-apy with valganciclovir in a recent kidney transplant recipient ...
A. Shingare, N. Dhope, M. Bahadur
semanticscholar   +1 more source

Long-term Efficacy of Oral Valganciclovir in Presumed Cytomegalovirus Unilateral Hypertensive Anterior Uveitis

Ocular immunology and inflammation
Purpose To describe long-term efficacy and safety of oral valganciclovir in the treatment of presumed cytomegalovirus (CMV) unilateral hypertensive anterior uveitis. Methods Retrospective review of 40 patients (40 eyes).
Abdulsalam M. Dheyab, A. AlBloushi, Asma Al-Zuabi, Sulaiman AlTariqi, Mohannad F. Tobaigy, A. Alfawaz, A. Abu El‐Asrar   +6 more
semanticscholar   +1 more source

Letermovir conversion after valganciclovir treatment in cytomegalovirus high‐risk abdominal solid organ transplant recipients may promote development of cytomegalovirus‐specific cell mediated immunity

Transplant Infectious Disease, 2021
To evaluate the association of conversion from valganciclovir to letermovir on cytomegalovirus‐specific cellular immunity.
M. Jorgenson, Hanna L. Kleiboeker, Neetika Garg, Sandesh Parajuli, D. Mandelbrot, J. Odorico, Christopher M Saddler, Jeannina A Smith   +7 more
semanticscholar   +1 more source

The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients

Transplant Infectious Disease, 2021
Persistent viral replication resulting in ongoing cytomegalovirus (CMV) viremia despite adequate therapy is difficult to manage and associated with negative outcomes. We report a case series of kidney transplant recipients receiving adjunctive letermovir
M. Jorgenson, J. Descourouez, Neetika Garg, Sandesh Parajuli, D. Mandelbrot, J. Odorico, Christopher M Saddler, Jeannina A Smith   +7 more
semanticscholar   +1 more source